Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts. Show more

Location: 201 Brookline Avenue, Boston, MA, 02215, United States | Website: https://www.tangotx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

612.4M

52 Wk Range

$1.03 - $12.02

Previous Close

$5.65

Open

$5.74

Volume

620,077

Day Range

$5.64 - $5.96

Enterprise Value

375.2M

Cash

216.7M

Avg Qtr Burn

-33.84M

Insider Ownership

12.59%

Institutional Own.

97.75%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.